Moderna's omicron-containing bivalent booster candidate, mrna-1273.214, demonstrates significantly higher neutralizing antibody response against omicron subvariants ba.4/5 compared to currently authorized booster

Mrna-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including omicron ba.1 and ba.4/5 subvariants, ancestral virus, alpha, beta, delta, and gamma moderna has completed regulatory submissions for mrna-1273.214 in eu, uk, and australia, expects to complete most remaining filings this week company simultaneously developing mrna-1273.222, a bivalent candidate based on ba.4/5, consistent with recent fda guidance cambridge, ma / accesswire / july 11, 2022 / moderna, inc., (nasdaq:mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced new clinical data on its bivalent omicron (ba.1) booster candidate, mrna-1273.214. one month after administration in previously vaccinated and boosted participants, a 50 Μg booster dose of mrna-1273.214 elicited significantly higher neutralizing antibody responses against the omicron subvariants ba.4 and ba.5 compared to the currently authorized booster (mrna-1273) regardless of prior infection status or age (adults over 18, greater or less than 65 years old).
MRNA Ratings Summary
MRNA Quant Ranking